MSS-type Advanced Colorectal Cancer
Conditions
Interventions
Intervention group:Sindilizumab injection + furaquinib capsule + tegumentary capsule
Sponsors
Three department of internal medicine, College of traditional Chinese medicine, Guangdong, China
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? Patients with pathologically confirmed colorectal cancer, staged as stage IV patients; ? Colorectal cancer patients with histologically confirmed MSS; ? Patients with disease progression or resistance to at least two or more systemic chemotherapy regimens; ? Card style score (Karnofsky, KPS) = 60 points; ? Those with normal bone marrow, liver, kidney, heart, and lung function; ? Age between 18 and 80 years; ? Informed consent to participate in this study, with good compliance and those who could be followed up.
Exclusion criteria
Exclusion criteria: ? Had brain metastases, severe brain disease, or mental illness that affected the patient's ability to self-report; ? Those with comorbid active tuberculosis and other severe infectious diseases; ? Pregnant or lactating women; ? Those with severe allergic constitution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Incidence rate of adverse drug events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Overall survival;KPS score; | — |
Countries
China
Contacts
Public ContactLi Liu-ning
Three department of internal medicine, College of traditional Chinese medicine, Guangdong, China
Outcome results
None listed